



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/304,859	05/04/1999	DAVID BERD	1225/IE251-U	1252

7590 01/02/2002

DARBY & DARBY P C
805 THIRD AVENUE
NEW YORK, NY 10022

EXAMINER

HUNT, JENNIFER ELIZABETH

ART UNIT

PAPER NUMBER

1642

DATE MAILED: 01/02/2002 21

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No. 09/304,859	Applicant(s) Berd, David
Examiner Jennifer Hunt	Art Unit 1642



-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136 (a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1) Responsive to communication(s) filed on Sep 27, 2001

2a) This action is FINAL. 2b) This action is non-final.

3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11; 453 O.G. 213.

Disposition of Claims

4) Claim(s) 2, 3, 5-10, 12-17, and 25-56 is/are pending in the application.

4a) Of the above, claim(s) _____ is/are withdrawn from consideration.

5) Claim(s) _____ is/are allowed.

6) Claim(s) 2, 3, 5-10, 12-17, and 25-56 is/are rejected.

7) Claim(s) _____ is/are objected to.

8) Claims _____ are subject to restriction and/or election requirement.

Application Papers

9) The specification is objected to by the Examiner.

10) The drawing(s) filed on _____ is/are objected to by the Examiner.

11) The proposed drawing correction filed on _____ is: a) approved b) disapproved.

12) The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. § 119

13) Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d).

a) All b) Some* c) None of:

- Certified copies of the priority documents have been received.
- Certified copies of the priority documents have been received in Application No. _____.
- Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

*See the attached detailed Office action for a list of the certified copies not received.

14) Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e).

Attachment(s)

15) Notice of References Cited (PTO-892) 18) Interview Summary (PTO-413) Paper No(s). _____

16) Notice of Draftsperson's Patent Drawing Review (PTO-948) 19) Notice of Informal Patent Application (PTO-152)

17) Information Disclosure Statement(s) (PTO-1449) Paper No(s). _____ 20) Other: _____

Art Unit: 1642

Response to Amendment

1. Acknowledgment is made of applicant's cancellation of claims 1, 4, and 18-24, and addition of new claims 25-26. Claims 2-3, 5-10, 12-17, and 25-26 are pending in the application and considered herein.

Claim Rejections Withdrawn

2. All rejections of claims 1, 4, and 18-24 are withdrawn in light of the cancellation thereof.

Claim Objections

3. Claim 5 is objected to because it appears that the recitation of "cyclophosphomice" in line 10 should recite --cyclophosphamide--.

4. Claim 11 is objected to because it depends from a canceled claim.

Appropriate correction is required.

Claim Rejection Maintained

5. The rejection of pending claims 2-3, 5-10, and 12-17 under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1 and 2 of Bed (US #5,290,551), in view of Elliot et al. (US #5,478,556), or Mankiewicz et al., *Cancer Immunol. Immunother.*, Vol. 2, pages 27-39, 1977, or Humphrey et al., *Surgery, Gynecology, and*

Art Unit: 1642

Obstetrics, pages 437-442, March 1971 is maintained for reasons of record, and applied to newly added claims 25-56.

Claim 1 of US #5,290,551 recites a vaccine composition which is a tumor cell extract wherein the tumor cells are melanoma cells. The extract is conjugated to a hapten, the same tumor type as the patient's tumor, not allogenic to said patient and incapable of growing in the patient's body after injection. Claim 2 of '551 recites a method of treating melanoma comprising administering cyclophosphamide, followed by a therapeutically effective amount of the vaccine of claim 1. The disclosure teaches a therapeutically effective amount that includes administration of the vaccine more than 6 times (column 4, line 65-66 and column 5, line 1-11), administration of a 300mg/M² dose of cyclophosphamide prior to vaccination, including administration 3 days before vaccination (column 4, line 60), a dosage of tumor cells including 10 X 10⁶ cells, which is at least 10⁶ tumor cells per dose. (column 3, line 37), vaccination protocols which sensitize patient to the hapten prior to vaccination (column 5, line 52), vaccination protocols which do not sensitize patient to the hapten prior to vaccination (column 4, example 1) and that the effective amount is indicated by infiltration of the tumor by activated T lymphocytes (column 3, line 67-68). All of the treatments are administered to human patients. While the method does not explicitly recite a maximum dose of 7.5 X 10⁶ cells per dose, this specific dose would be an obvious variation of the instant methods, encompassed by art known techniques of dosage optimization.

Art Unit: 1642

With regard to claims 9-10 and 20-21 of applicant's invention, claim 1 of '551 specifically recites use of a hapten selected from the group comprising dinitrophenyl....etc.

With regard to claims 12 and 22-24 of applicant's invention, claim 1 of '551 specifically recites administration with an adjuvant, wherein the adjuvant is *Bacille Calmette-Guerin*.

Berd US #5,290,551 fails to teach weekly injections or administration of cyclophosphamide (CY) only prior to the first dose of the vaccine.

Vaccination protocols comprising weekly booster injections of inactivated autologous tumor cell extract, and administration of cyclophosphamide prior to the first injection is known in the art.

See for example, Elliot (US # 5,478,556), which at column 4 describes administration of an autologous tumor vaccine with prior administration of cyclophosphamide (CY), and weekly vaccine administration protocol, column 4, lines 20-25.

See also for example, Mankiewicz et al., which at page 28, column 2, describes administration of an autologous tumor vaccine with weekly vaccine administration protocol.

See also for example, Humphrey et al., which at page 437, column 2, describes administration of an autologous tumor vaccine with weekly vaccine administration protocol.

Therefore it would have been *prima facie* obvious to one of ordinary skill in the art at the time the invention was made to administer weekly injections of the composition disclosed in Berd US #5,290,551, and to administer cyclophosphamide prior to the first injection for the purpose of optimizing the claimed "therapeutically effective amount", because weekly boosters

Art Unit: 1642

and administration of cyclophosphamide prior to the first injection were well known vaccine protocols, as exemplified in Elliot et al., Mankiewicz et al., and Humphrey et al.

Therefore the instant claims 1-10 and 12-24 are obvious over claims 1-2 of US 5,290,551 and thus are rejected under the judicially created doctrine of obviousness-type double patenting.

6. The rejection of pending claims 2-3, 5-10, and 12-17 under 35 U.S.C. 103(a) as being unpatentable over Berd (US# 5,290,551), or Berd et al., Cancer Research, Vol. 51, pages 2731-2734, May 15, 1991, or Berd et al., Proceedings of the American Association for Cancer Research, Vol. 35, pages 667-678, March 1994, in view of Elliot et al. (US #5, 478, 556), or Mankiewicz et al., Cancer Immunol. Immunother., Vol. 2, pages 27-39, 1977, or Humphrey et al., Surgery, Gynecology, and Obstetrics, pages 437-442, March 1971, is maintained for reasons of record, and applied to newly added claims 25-26.

‘551 teaches a vaccine composition and method of inducing an anti-tumor response comprising administering the composition, in which the composition is a tumor cell extract wherein the tumor cells are melanoma cells. The tumor cell extract is conjugated to a hapten, the same tumor type as the patient’s tumor, not allogenic to said patient and incapable of growing in patient’s body after injection. This composition was administered more than 6 times. (col 4, lines 65-66 and col 5, lines 1-11) Three days prior to vaccination, patients were administered 300mg/M2 of cyclophosphamide. (Col 4, line 60) A dosage including 10×10^6 tumor cells was used, which is at least 10^6 tumor cells per dose. (column 3, line 37) The hapten is dinitrophenyl

Art Unit: 1642

and is administered with the adjuvant *Bacillus Calmette-Guerin*. (col 5, lines 54-57) '551 teaches methods in which the patients is first sensitized to the hapten (col 5, line 52), and methods in which the patient is not first sensitized to the hapten. (col 4, example 1) The treatment is administered to human patients. The anti-tumor response induced is tumor infiltration by activated T lymphocytes. (Col 3, lines 67-68) '551 does not teach weekly administration of the composition, or administration of cyclophosphamide only prior to the first dose of the vaccine. While the method does not explicitly recite a maximum dose of 7.5×10^6 cells per dose, this specific dose would be an obvious variation of the instant methods, encompassed by art known techniques of dosage optimization.

Berd et al., *Cancer Research*, teaches a composition and method of inducing an anti-tumor response comprising administering the composition, in which the composition is a tumor cell extract wherein the tumor cells are melanoma cells. The tumor cell extract is conjugated to a hapten, the same tumor type as the patient's tumor, not allogenic to said patient and incapable of growing in patient's body after injection. This composition was administered more than 6 times. Three days prior to vaccination, patients were administered 300mg/M2 of cyclophosphamide. A dosage including 10×10^6 tumor cells was used, which is at least 10^6 tumor cells per dose. The hapten is dinitrophenyl and is administered with the adjuvant *Bacillus Calmette-Guerin*. Berd et al., *Cancer Research*, teaches methods in which the patients is first sensitized to the hapten. The treatment is administered to human patients. The anti-tumor response induced is tumor infiltration by activated T lymphocytes. While the method does not explicitly recite a maximum

Art Unit: 1642

dose of 7.5×10^6 cells per dose, this specific dose would be an obvious variation of the instant methods, encompassed by art known techniques of dosage optimization. (see for example, abstracts and Materials and Methods)

Berd et al., Proceedings of the American Association for Cancer Research teaches a composition and method of inducing an anti-tumor response comprising administering the composition, in which the composition is a tumor cell extract wherein the tumor cells are melanoma cells. The tumor cell extract is conjugated to a hapten, the same tumor type as the patient's tumor, not allogenic to said patient and incapable of growing in patient's body after injection. This composition was administered more than 6 times. Three days prior to vaccination, patients were administered 300mg/M2 of cyclophosphamide. The hapten is dinitrophenyl and is administered with the adjuvant *Bacillus Calmette-Guerin*. Berd et al., Proceedings of the American Association for Cancer Research, teaches methods in which the patients is first sensitized to the hapten, and methods in which the patient is not first sensitized to the hapten. The treatment is administered to human patients. The anti-tumor response induced is tumor infiltration by activated T lymphocytes. (See entire abstract)

Berd, US Patent #5,290,551, Berd et al., Cancer Research, and Berd et al., Proceedings of the American Association for Cancer Research, fail to teach weekly injections or administration of cyclophosphamide only prior to the first dose of the vaccine.

Art Unit: 1642

Vaccination protocols comprising weekly booster injections of inactivated autologous tumor cell extract, and administration of cyclophosphamide prior to the first injection is known in the art.

See for example, Elliot (US # 5,478,556), which at column 4 describes administration of an autologous tumor vaccine with prior administration of CY and weekly vaccine administration protocol, column 4, lines 20-25.

See also for example, Mankiewicz et al., which at page 28, column 2, describes administration of an autologous tumor vaccine with weekly vaccine administration protocol.

See also for example, Humphrey et al., which at page 437, column 2, describes administration of an autologous tumor vaccine with weekly vaccine administration protocol.

Therefore it would have been *prima facie* obvious to one of ordinary skill in the art at the time the invention was made to administer weekly injection of the composition disclosed in Berd, and to administer cyclophosphamide prior to the first injection for the purpose of optimizing the “therapeutically effective amount”, because weekly boosters and administration of cyclophosphamide prior to the first injection were well known vaccine protocols, as taught in Elliot et al., Mankiewicz et al., and Humphrey et al.

Arguments

Applicant argues that many of the references do not teach CY administration, or instead teach administration of CY prior to all vaccinations. Applicant specifically notes that while

Art Unit: 1642

Elliot teaches that patients are usually administered CY two to three weeks before vaccine protocols, that Elliot "fails to mention the significance of excluding any subsequent CY administrations".

Applicant further argues that the references do not render the instant claims obvious because unexpected results are achieved when the vaccine taught in both the prior art and in the instant application is administered weekly, rather than monthly, and a CY dose is administered before administration of the vaccine and not afterwards (specifically, an unexpected enhanced immune response is generated). Applicant cites the examiner's arguments from the previous office action as further support of this contention, arguing that the claims now are drawn to the methods which produce unexpected results. Applicant's arguments filed 9-27-2001 have been fully considered but they are not persuasive.

With regard to the teachings of the prior art, Elliot teaches that an initial dose of CY, followed by a vaccine is a known protocol. Elliot need not explicitly state that no second dose of CY was administered. The teachings do not include a second dose, thus the method of Elliot teaches a vaccine protocol in which only one dose of CY is administered, prior to initiation of a vaccination protocol.

With regard to the arguments of unexpected results, as set forth in the previous office action, the specification teaches four dosage regimens (A-D) in example 15, three of which (B-D) describe weekly vaccine administration. Of the three weekly protocols, two result in inferior immune stimulation, and one results in enhanced immune stimulation, when compared to q 28

Art Unit: 1642

day administration. The specification concludes thus that dosage may have significant influence on treatment efficacy, however this is a speculative conclusion, and the results set forth in the specification fail to provide the alleged unexpected equivalent or superior results when weekly vaccines are administered. These results constitute mere optimization of dosage regimens. Certainly, that the weekly administration of a vaccine produces equal or enhanced immune response compared to a q 28 day administration is not surprising. Further, two of the three weekly protocols resulted in vastly decreased response, when compared to the q 4 week regimen, and it is not clear from the specification as filed what difference between the vaccine protocols caused this large discrepancy.

As set forth previously, and expanded above, weekly vaccine protocols for cancer vaccines and immunotherapies were known in the art, and alteration to a weekly dosage regimen would not constitute undue experimentation but rather simply optimization. The courts have held that “[Where the general conditions of a claim are disclosed in the prior art, it is not inventive to discover the optimum or workable ranges by routine experimentation.” In re Aller, 220 F.2d 454, 456, 105 USPQ 233, 235 (CCPA 1955) (Claimed process which was performed at a temperature between 40C and 80C and an acid concentration between 25 and 70% was held to be prima facie obvious over a reference process which differed from the claims only in that the reference process was performed at a temperature of 100C and an acid concentration of 10%). Further, as set forth above, there is no clear evidence that the weekly administration of a vaccine results in overall increased efficacy. Although it is clear that the protocol of group D resulted in enhanced

Art Unit: 1642

treatment, there is no evidence that this increased efficacy is a result of weekly vaccine administration. In fact, there is contrary evidence of such, since the weekly administrations to Groups B and C resulted in poor response. Further, the specification provides no guidance as to what the difference between the protocols of B and C to D was that resulted in the differences. It is not until after filing, with further experimentation that lead applicant to a very specific regimen that happened to produce enhanced results similar to those of Group D.

With regard to the rule 1.132 declaration, which points to a specific alteration of cyclophosphamide and vaccine administration change as critical to the unexpected results, is not commensurate in scope with the claims.

The claims are broadly drawn to any weekly protocol for vaccine administration, including different cyclophosphamide (CY) dosages, different adjuvants, etc. The protocol which achieved unexpected results, however, was far more specific, and it is clear that numerous weekly administrations do not include the same results (see Groups B and C from the instant specification, Example 15)

The declaration and post filing evidence clearly states that it is the single administration of cyclophosphamide administration, in combination with an induction dose of vaccine and then weekly vaccine administration which achieves unexpected results. Further, the evidence supplied by the post filing evidence indicates that the specific enhances DTH response is only achieved when a specific dose of cyclophosphamide is administered at a specific time, in combination with a proper priming dose.

Art Unit: 1642

The claims are drawn to a broad range of possible dosages, including numerous CY dosage variants, any number of or absence of adjuvants, etc. The claims (and the specification) do not even mention the induction dose, cited by applicant as critical for the alleged unexpected results. Thus claims drawn to any and all weekly administrations of the vaccine and variant protocols are not commensurate in scope with the alleged unexpected results. Further, that the weekly administration of a vaccine produces an equal or stronger immune response to an immunogen would not be unexpected, because the dose frequency is greater. As noted in the previous office action, and cited in part by applicant, it was a very specific vaccine administration protocol which generated the alleged unexpected results, and it is further noted that these parameters are not instantly claimed.

Therefor the as set forth above, it would have been *prima facie* obvious to modify the vaccine protocol taught in Berd et al. by administering weekly injections and one would have been motivated to do so for optimization of vaccine protocol. Further, the results achieved are not unexpected because the unexpected results described in the declaration by Dr. Berd and in the post filing evidence were neither disclosed in the instant specification, nor commensurate in scope with the instant claims.

Conclusion

Art Unit: 1642

7. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

No claims are allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jennifer Hunt, whose telephone number is (703) 308-7548. The examiner can normally be reached Monday through Thursday 6:30am to 5:00pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Anthony Caputa can be reached at (703) 308-3995. The fax number for the group is (703) 305-3014 or (703) 308-4242.

Art Unit: 1642

Communications via internet e-mail regarding this application, other than those under 35 U.S.C. 132 or which otherwise require a signature, may be used by the applicant and should be addressed to **[anthony.caputa@uspto.gov]**.

All internet e-mail communications will be made of record in the application file. PTO employees do not engage in Internet communications where there exists the possibility that sensitive information could be identified or exchanged unless the record includes a properly signed express waiver of the confidentiality requirements of U.S.C. 122. This is more clearly set forth in the Interim Internet Usage Policy published in the Official Gazette of the Patent and Trademark on February 25, 1997 at 1195 OG 89.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the group receptionist, whose telephone number is (703) 308-0196.

Jennifer Hunt

December 30, 2001

A handwritten signature in black ink, appearing to read "Jennifer Hunt". The signature is somewhat stylized and includes a small, distinct mark or initial at the beginning.